The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cells
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology
Link
http://link.springer.com/article/10.1007/s00345-018-2382-8/fulltext.html
Reference33 articles.
1. Azoitei A, Merseburger AS, Godau B, Hoda MR, Schmid E, Cronauer MV (2017) C-terminally truncated constitutively active androgen receptor variants and their biologic and clinical significance in castration-resistant prostate cancer. J Steroid Biochem Mol Biol 166:38–44
2. Lapouge G, Erdmann E, Marcias G, Jagla M, Monge A, Kessler P, Serra S, Lang H, Jacqmin D, Bergerat JP, Céraline J (2007) Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation—a new paradigm for cooperation among prostate tumor cells. Int J Cancer 121:1238–1244
3. Han D, Gao S, Valencia K, Owiredu J, Han W, de Waal E, Macoska JA, Cai C (2017) A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer. Oncotarget 8:6796–6808
4. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM (2014) Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510:278–282
5. Chan SC, Selth LA, Li Y, Nyquist MD, Miao L, Bradner JE, Raj GV, Tilley WD, Dehm SM (2015) Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res 43:5880–5897
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. BET bromodomain inhibitors PFI-1 and CPI-203 suppress the development of follicular lymphoma via regulating Wnt/β-catenin signaling;Heliyon;2024-03
2. Therapeutic Approaches to Targeting Androgen Receptor Splice Variants;Cells;2024-01-04
3. Combined BET and MEK Inhibition synergistically suppresses melanoma by targeting YAP1;Theranostics;2024
4. BET Bromodomain Inhibitors as an Emerging Class of Anticancer Agents;Handbook of Cancer and Immunology;2023-11-08
5. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors;Advances in Cancer Research;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3